No changes in Australian domestic IP warranted, say generic drugmakers
Members of the generic drugs industry are calling on the Australian government to support efforts to protect access to medicines in negotiations on the Trans Pacific Partnership Agreement (TPPA).
According to Australian trade group Generic Medicines Industry Association (GMiA), the USA is currently pushing a series of measures that could potentially undermine the Pharmaceutical Benefits Scheme (PBS) and restrict access to generic medicines in Australia.
The USA is recommending a controversial proposal on pharmaceuticals for inclusion in the TPPA, which includes provisions on exclusive rights over patent linkage; patent term extensions; and extensions to periods of data exclusivity. The extension of Australia’s periods of intellectual property will significantly increase the cost of medicines to the Australian public, the GMiA notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze